Faricimab achieves inactive disease in veteran population with AMD
Click Here to Manage Email Alerts
SEATTLE — Patients with age-related macular degeneration in a veteran population experienced an increase in inactive disease after treatment with faricimab, according to a poster presented here.
“Faricimab, or Vabysmo (Genentech), was effective at creating inactive disease to a statistically significant degree in age-related macular degeneration patients in a national cohort study of the Veterans Affairs,” Daniel Fraser told Healio at the Association for Research in Vision and Ophthalmology meeting.
Fraser and colleagues investigated the short-term efficacy of faricimab on disease activity in a nationwide U.S. veteran cohort, which included 572 eyes, 55% of which were diagnosed with exudative AMD and 38% with diabetic macular edema. All eyes received at least one injection of faricimab in 2022, while 235 eyes received at least three injections of aflibercept immediately followed by four faricimab injections.
There were significantly more AMD eyes with inactive disease (P < .001) after the first injection of faricimab, but this was not seen in DME. Significantly more eyes with DME had disease improvement after treatment with faricimab (P = .004), however.
In addition, the short-term treatment interval remained stable in the AMD aflibercept-faricimab comparison cohort and increased in the DME aflibercept-faricimab comparison cohort. Those with AMD and inactive disease in the comparison cohort also experienced increased treatment intervals after their first faricimab dose, while those with DME in the comparison cohort did not.
“Faricimab may facilitate disease control in exudative AMD recalcitrant to aflibercept,” the authors wrote. “Ongoing follow-up of this study cohort will assess the feasibility of long-term treatment interval extension with faricimab and decreasing the treatment burden for patients.”
Collapse
Fraser D, et al. Effectiveness of intravitreal faricimab in a United States veteran population. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Read more about
Click Here to Manage Email Alerts